When stratifying TARGET-AML patients according to the 25% highest and lowest BACH2 levels, expectedly, the age of diagnosis (mean 2121 days ± 1947 vs. 4075 days ± 2137) was significantly lower for the high-expressing group (Fig. 7B). Here, BACH2 is linked to acute myeloid leukemia.